Zhen-Yu Liang (Attending Physician)
Department of Medicine: Respiratory Medicine
Education: PhD
Position: Deputy Director
Affiliation: The First Hospital of Guangzhou Medical University
Address: No. 1838, Guangzhou Avenue North, Guangzhou, Guangdong, China
Specialist Profile：
The First Hospital of Guangzhou Medical University/Guangzhou Institute of Respiratory Health
Secretary of the Chinese Society of Respiratory Diseases, Chronic Obstructive Pulmonary Disease Group; Standing Committee Member of the Young Physicians Branch of Guangzhou Physicians Association; Guangzhou High-Level Talent (Youth Reserve); Expert Panel Member of the Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2021 Revision)
Research interests
Lung disease, chronic obstructive; asthma; early prevention and control; screening; diagnosis; treatment; primary health care; general practitioner
Research Projects
1. Natural Science Foundation of Guangdong Province (Guangdong Provincial Science and Technology Department), 2015A030310497, Application of data mining technology to identify endogenous asthma phenotypes
2. Guangzhou Science and Technology Plan Project (Guangzhou Science and Technology Bureau), 103270653062, Research on multi-dimensional evaluation index system of quantitative CT for chronic obstructive pulmonary disease based on machine learning
3. Guangzhou Postdoctoral Research Project Start-up Fee (Guangzhou Municipal Bureau of Human Resources and Social Security), 19800226, Application of data mining technology to construct a classification model of endogenous phenotypes of chronic obstructive pulmonary disease
Academic achievements
[1] Liang Z, Zhong N, Chen R, Ma Q, Sun Y, Wen F, Tal-Singer R, Miller B E, Yates J, Song J, Compton C, Ji B, Wu L, Yang Y, Jones P, Zheng J. Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale[J]. ERJ Open Res,2021,7(3):00201.
[2] Chen Y J#, Jian W H#, Liang Z Y#, Guan W J#, Liang W H#, Chen R C, Tang C L, Wang T, Liang H R, Li Y M, Liu X Q, Sang L, Cheng L L, Ye F, Li S Y, Zhang N F, Zhang Z, Fang Y, He J X, Zhong N S, Zheng J P. Earlier diagnosis improves COVID-19 prognosis: a nationwide retrospective cohort analysis[J]. Ann Transl Med,2021,9(11):941.
[3] Xu J#, Liang Z#, Jian W#, Li J, Tang G, Mo X, Zhang D, Zheng J, Qian Y, Liu J, Li S. Changes of quantitative CT-based airway wall dimensions in patients with COVID-19 during early recovery[J]. J Thorac Dis,2021,13(3):1517-1530.
[4] Liang Z#, Long F#, Deng K#, Wang F#, Xiao J, Yang Y, Zhang D, Gu W, Xu J, Jian W, Shi W, Zheng J, Chen X, Gao Y, Luo Q, Stampfli M R, Peng T, Chen R. Dissociation between airway and systemic autoantibody responses in chronic obstructive pulmonary disease[J]. Ann Transl Med,2020,8(15):918.
[5] Wang Z, Liu H, Wang F, Yang Y, Wang X, Chen B, Stampfli M R, Zhou H, Shu W, Brightling C E, Liang Z*, Chen R*. A Refined View of Airway Microbiome in Chronic Obstructive Pulmonary Disease at Species and Strain-Levels[J]. Front Microbiol,2020,11:1758.
[6] Liang Z#, Wang F#, Zhang D#, Long F#, Yang Y#, Gu W, Deng K, Xu J, Jian W, Zhou L, Shi W, Zheng J, Chen X, Chen R. Sputum and serum autoantibody profiles and their clinical correlation patterns in COPD patients with and without eosinophilic airway inflammation[J]. J Thorac Dis,2020,12(6):3085-3100.
[7] Li R, Liu J, Fang Z, Liang Z*, Chen X*. Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma[J]. Front Pharmacol,2020,11:572627.
[8] Liang Z#, Long F#, Wang F#, Yang Y, Xiao J, Deng K, Gu W, Zhou L, Xie J, Jian W, Chen X, Jiang M, Zheng J, Peng T, Chen R. Identification of clinically relevant subgroups of COPD based on airway and circulating autoantibody profiles[J]. Mol Med Rep, 2019, 20(3):2882-2892.
[9] Liang Z Y, Chen R C. Revision history and reflections of the chronic obstructive pulmonary disease treatment guidelines (2021 revised edition)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases,2021,44(3):165-166.
[10] Liang Z Y, Wang F Y, Chen R C. Interpretation of important updates to the guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (2021 revision) and outlook[J]. International Journal of Respiratory,2021,41(19):1457-1461.
[11] Liang Z Y, Wang F Y, Wang L W, Qiu C, Chen R C. Interpretation of the highlights of the newly cited literature and updates of the 2020 edition of the global creation of chronic obstructive pulmonary disease[J]. Chinese Journal of Tuberculosis and Respiratory,2020,43(4):350-355.
[12] Chronic Obstructive Pulmonary Disease Group of the Chinese Medical Association Respiratory Diseases Branch, Chronic Obstructive Pulmonary Working Committee of the Chinese Physicians Association Respiratory Physicians Branch. Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (2021 Revision) [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2021, 44(3): 170-205. (Expert panel member)
[13] National Center of Respiratory Medicine, The First Hospital of Guangzhou Medical University, National Clinical Medical Research Center for Respiratory Diseases,Asthma Group of the Chinese Medical Association, Division of Respiratory Diseases. Chinese expert consensus on the diagnosis and treatment of eosinophilia-associated lung diseases [J]. Chinese Medical Journal,2022,102(1):21-35.(Expert group member)